Abstract Details

Title Real-world evidence on HRQoL of therapy-resistant migraine patients undergoing preventive treatment in an ambulatory care setting

Topic Headache

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 205

Objective

The objective of this investigation was to analyze the health-related quality of life (HRQoL) in patients receiving different types of preventive migraine substances in a real-world ambulatory care setting.

Background Migraine is associated with a high burden of disease and significantly decreases the patients’ HRQoL calling for holistic treatment approaches. Therefore, generating evidence of relevant clinician- and patient-reported outcomes (PROs) for different treatments is an essential prerequisite for advancing personalized care paths.

Design/Methods In this single-center retrospective observational study, patients with a therapy-resistant migraine were treated along different established preventive substance groups compared to no treatment and tracked using web-based software. At two different time points - baseline (T0) and 1 month follow-up after treatment initiation (T1) - clinical parameters including migraine days and validated PROs (MIDAS, EQ-5D-5L-VAS, 7-domain score PROMIS-29) were collected. Descriptive analysis and One-way Anova test for statistical mean differences, confirmed by a linear mixed model for multivariate repeated measures as well as Pearson correlations were performed.

Results Of n=103 patients included, 79.6% (83) patients received monoclonal antibodies, 12 other preventive substances and 9 no substances. One-way Anova tests stratified by therapy and time points showed significant mean differences in the amount of headache days, in the EQ-5D-5L-VAS and in the PROMIS-domains of pain intensity, pain disturbance and social roles. The linear mixed model calculated a reduction of headache days [SD] by 9.29 days [2.35] (p= 7.64e-05) at T1. Similarly, the EQ-5D-5L-VAS improved by 8.57 score points [1.58] (p= 5.92e-08). The Pearson Coefficient revealed correlations between the PROMIS domains (medium strong) and the EQ-5D-5L-VAS (strong) with the amount of headache days.

Conclusions

Patients receiving a preventive treatment presented a decrease in headache days and an increase in certain PROMs, demonstrating that preventive migraine treatment in an ambulatory setting can be beneficial for HRQoL.

Authors/Disclosures
Schirin Sulaiman (heartbeat medical solutions GmbH) PRESENTER	Miss Sulaiman has nothing to disclose.
	No disclosure on file
	No disclosure on file
Markus Jahn	Mr. Jahn has nothing to disclose.
	No disclosure on file

��ɫ��

��ɫ��